Susan Rodriguez Biography and Net Worth

Insider of Ardelyx

Ms. Susan Rodriguez is an Independent Director at Heron Therapeutics, Inc. She is on the Board of Directors at Veradigm, Inc., Heron Therapeutics, Inc., Cuba Emprende Foundation and The Santa Barbara Humane Society.
Ms. Rodriguez was previously employed as a Chief Commercial Officer by Ardelyx, Inc., a Chief Executive Officer by Tolmar Pharmaceuticals, Inc., a Chief Executive Officer by TOLMAR, Inc., a Vice President & General Manager by TAP Holdings, Inc., a Vice President-Global Marketing by Abbott Laboratories, and a Client Manager by Arbor Pharmaceuticals LLC.

She received her undergraduate degree from the University of Pennsylvania and a graduate degree from the University of Pennsylvania.

What is Susan Rodriguez's net worth?: The estimated net worth of Susan Rodriguez is at least $2.06 million as of August 21st, 2023. Rodriguez owns 348,687 shares of Ardelyx stock worth more than $2,064,227 as of December 5th. This net worth approximation does not reflect any other investments that Rodriguez may own. Learn More about Susan Rodriguez's net worth.
How do I contact Susan Rodriguez?: The corporate mailing address for Rodriguez and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Susan Rodriguez's contact information.
Has Susan Rodriguez been buying or selling shares of Ardelyx?: Susan Rodriguez has not been actively trading shares of Ardelyx during the last quarter. Most recently, Susan Rodriguez sold 4,733 shares of the business's stock in a transaction on Monday, August 21st. The shares were sold at an average price of $3.55, for a transaction totalling $16,802.15. Following the completion of the sale, the insider now directly owns 348,687 shares of the company's stock, valued at $1,237,838.85. Learn More on Susan Rodriguez's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes Robert Blanks (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, Ardelyx insiders bought shares 7 times. They purchased a total of 1,371,406 shares worth more than $5,780,176.94. In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 580,304 shares worth more than $3,050,503.57. The most recent insider tranaction occured on November, 21st when insider Elizabeth A Grammer sold 5,995 shares worth more than $33,212.30. Insiders at Ardelyx own 4.8% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 11/21/2025.

Susan Rodriguez Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/21/2023	Sell	4,733	$3.55	$16,802.15	348,687
8/21/2023	Sell	4,733	$3.55	$16,802.15	348,687
8/22/2022	Sell	3,420	$0.98	$3,351.60	286,173
6/6/2022	Sell	43,920	$0.65	$28,548.00	289,593
9/16/2020	Sell	6,087	$6.11	$37,191.57

Susan Rodriguez Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $5.92

$5.73

$5.93

50 Day Range

MA: $5.47

$4.94

$6.13

2 Week Range

Now: $5.92

$3.21

$6.78

Volume

2,512,726 shs

Average Volume

2,556,201 shs

Market Capitalization

$1.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55